Effects of the prototype serotonin 5-HT1B/1D receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP8–37 on myocardial reactive hyperemic response in conscious dogs-Reference-Cited by-同舟云学术

Effects of the prototype serotonin 5-HT1B/1D receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP8–37 on myocardial reactive hyperemic response in conscious dogs

Published:2009-11 Issue:1-3 Volume:623 Page:96-102
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Lynch Joseph J.,Shen You-Tang,Pittman Tamara J.,Anderson Kenneth D.,Koblan Kenneth S.,Gould Robert J.,Regan Christopher P.,Kane Stefanie A.

Publisher

Elsevier BV

Subject

Pharmacology

Reference56 articles.

1. Effects of antiaggregant and anti-inflammatory doses of aspirin on coronary hemodynamics and myocardial reactive hyperemia in conscious dogs;Andrieu;J. Cardiovasc. Pharmacol.,1999

2. Acute myocardial infarction after sumatriptan administration for cluster headache;Anghileri;Neurol. Sci.,2006

3. Effects of the calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS on alpha-CGRP-induced regional haemodynamic changes in anaesthetised rats;Arulmani;Basic Clin. Pharmacol. Toxicol.,2004

4. 5-HT receptors mediating contractions of the isolated human coronary artery;Bax;Eur. J. Pharmacol.,1993

5. Vascular actions of calcitonin gene-related peptide and adrenomedullin;Brain;Physiol. Rev.,2004

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Pharmacological Review of Calcitonin Gene-Related Peptide Biologics and Future Use for Chronic Pain;Cureus;2023-02-17

2. CGRP Inhibitors for the Treatment of Migraine;Successful Drug Discovery;2021-02-26

3. Novel synthetic treatment options for migraine;Expert Opinion on Pharmacotherapy;2020-12-28

4. Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials;Frontiers in Pharmacology;2020-01-24

5. Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine;Regulatory Toxicology and Pharmacology;2019-08